Qing Miao

Qing Miao

Auto-generated profile, based on publicly available information

Qing Miao

Xiyuan Hospital, China Academy of Chinese Medical Sciences, No. 1 Xiyuan Playground, Haidian District, Beijing 100091, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of Infection
Verified
Journal Article
Closed access
BXBo Xu
Bo Xu
CFCun-Yu Fan
Cun-Yu Fan
AWAnlu Wang
Anlu Wang
YZYi-Long Zou
Yi-Long Zou
YYYi-Han Yu
Yi-Han Yu
QMQing Miao
Qing Miao

29 June 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
DGDe-Hai Guo
De-Hai Guo
JHJin-Ping Hao
Jin-Ping Hao
XLXing-Jie Li
Xing-Jie Li
QMQing Miao
Qing Miao
QZQiong Zhang
Qiong Zhang
Background. Cough variant asthma (CVA) has no definitive diagnosis or pathogenic causes, and there is currently no effective and safe treatment. Methods. The network pharmacology was employed to investigate possible targets of Zhisou San (ZSS) in CVA treatment. The main chemical constituents of seven herbs in ZSS were collected based on the TCMSP. To explain the main mechanism, we sequentially screened the targets of each active ingredient and constructed the network of herb-ingredient-target-disease. The core targets of ZSS were further confirmed by the molecular docking analysis. Furthermore, pulmonary function, histopathology, and biochemical assays in mice were used to investigate the effect of ZSS on the treatment of CVA. Results. A total of 137 active ingredients and 86 potential targets for the ZSS in the treatment of CVA were screened, which were connected with the regulation of inflammatory response and immune balance, such as IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Toll-like receptor signaling pathway, MAPK signaling pathway, T-cell receptor signaling pathway, Th1 and Th2 cell differentiation, and other signaling pathways closely related to the pathogenesis of CVA. Thereinto, 29 core targets contained 8 of the highest scores and could evidently bind to components such as stigmasterol, quercetin, stemoninine B, luteolin, and β-sitosterol predicted by molecular docking. Furthermore, experiments in vivo were conducted for further validation that ZSS had essential effects on lung function and histopathology as well as the inflammatory state in CVA mice, which was significantly related to regulating the Th17/Treg immune balance to reduce inflammation as the important pharmacological mechanism. Conclusion. This study revealed that ZSS has multicomponent and multipathway characteristics of ZSS in the treatment of CVA, which was primarily associated with inflammation and Th17/Treg immune balance. This study provides a scientific foundation for systematically elaborating the pharmacological activities and mechanism of ZSS, as well as explaining the reliability of the TCM compatibility theory.

28 December 2024 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
BBBo Bian
Bo Bian
CGChang Ge
Chang Ge
FWFanwu Wu
Fanwu Wu
YFYiling Fan
Yiling Fan
JKJinli Kong
Jinli Kong
QMQing Miao
Qing Miao
Idiopathic pulmonary fibrosis (PF) is an irreversible and chronic inflammatory condition with limited therapeutic options and a high mortality rate. We aimed to determine the possible role and mechanisms of wogonin (WGN) on PF. A rat model of PF was established with intratracheally administrated with bleomycin (BLM), followed by intravenously injecting with WGN and weekly body weight measurements for four weeks. Hematoxylin–eosin (H&E) and Masson’s trichrome staining were implemented for histopathological analysis. In addition, the levels of fibrotic proteins and indicators of the mitogen-activated protein kinase (MAPK) pathway were assessed with Western blot. RT-quantitative (q)PCR experiment was conducted to investigate the fibrotic proteins’ mRNA expression. Ultimately, the concentrations of glutathione peroxidase (GSH-PX), malonaldehyde (MDA), and superoxide dismutase (SOD) were ascertained with appropriate kits. The results showed that WGN administration significantly reversed BLM-induced body weight reduction, alleviated pathological fibrosis, and reduced the Ashcroft score and the lung wet-to-dry weight ratio. Additionally, WGN suppressed the rise of fibrotic protein levels in BLM-treated rat’s lung tissues. Furthermore, WGN attenuated BLM-stimulated oxidative stress, as evidenced by the increased GSH-PX and SOD levels and decreased MDA levels in vivo. Finally, wogonin supplements significantly lowered the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK phosphorylation levels in the BLM-treated rat’s lung tissues. In conclusion, our study proved that PF induced by BLM administration can be mitigated by WGN treatment via suppressing the MAPK pathway, indicating that WGN is a candidate therapeutic agent for managing PF.

23 June 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
RQRuihan Qi
Ruihan Qi
HZHongchun Zhang
Hongchun Zhang
DLDemin Li
Demin Li
FGFeng Gao
Feng Gao
QMQing Miao
Qing Miao
ZCZhibin Chen
Zhibin Chen
Purpose. The study aimed to explore the efficacy and safety of Xinjia Xuanbai Chengqi granules (XJXBCQ) combined with conventional medicine in the treatment of acute exacerbation of chronic pulmonary disease (AECOPD). Patients and Methods. This multicentre, double-blind, parallel, placebo-controlled, randomised clinical trial conducted in China from January 2019 to February 2021 recruited 330 participants who were allocated into three groups. All participants underwent conventional basic treatment with oxygen therapy, antibiotics, and a bronchodilator. Besides, group A received XJXBCQ granules and budesonide suspension for inhalation; group B received XJXBCQ granules and half dosage of budesonide suspension; and group C received budesonide suspension and a placebo. All therapies lasted for 5 days, and participants were followed up for 30 days after discharge. The primary outcomes were efficacy, traditional Chinese medicine (TCM) syndrome score, and clinical symptom score. Secondary outcomes included the blood gas analysis, serum inflammatory markers, adverse events, mortality, theoretical discharge time, actual hospitalisation time, proportion of patients requiring invasive mechanical ventilation, proportion of patients transferred to an intensive care unit (ICU), and readmission rate within 30 days after discharge. Results. XJXBCQ adjunct with conventional treatment could significantly improve the total efficacy ( ). Meanwhile, group A showed significantly better results than group C in the TCM syndrome score, phlegm score, and Wexner constipation score ( ). For modified British medical research council (mMRC), on day 3 (−0.17, 95% confidence interval [CI]: −0.33–−0.01) and day 4 (−0.20, 95% CI: −0.39–−0.02), group A performed statistically better than group C. No significant differences in other secondary outcomes were detected. Conclusion. XJXBCQ is beneficial and safe for AECOPD treatment and could be considered an adjunctive therapy for promoting the relief of clinical symptoms. This trial is registered with ChiCTR1800016915.

1 September 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
BXBo Xu
Bo Xu
YYYihan Yu
Yihan Yu
JZJixian Zhang
Jixian Zhang
BJBo Jiang
Bo Jiang
LYLe Yan
Le Yan
YQYu Qi
Yu Qi
Purpose: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide. While Qianjin Weijin Decoction is widely used in China for lung cancer treatment, Jiawei Qianjin Weijin Decoction (JWWJD), a modified version, has shown enhanced anti-metastatic effects. However, its active components and underlying mechanisms remain unclear. Methods: The effect of JWWJD against NSCLC was evaluated in vitro and in vivo, and the mechanisms were identified in combination with transcriptomics. Network pharmacology and bioinformatics were used to construct an anti-NSCLC prognostic model with JWWJD. The correlation between the expression of the prognostic gene and clinicopathological features was evaluated. The main active components of JWWJD were identified by LC-MS/MS and its anticancer effect and mechanism were investigated in vitro and in vivo. Results: JWWJD-containing serum significantly suppressed cell proliferation and migration, and induced apoptosis in NCI-A549 and NCI-H23 cells. Among different concentrations tested, 20% drug-containing serum showed the most potent inhibitory effect on NSCLC progression (all P-values < 0.05). In a BALB/c-nu mouse xenograft model, oral administration of high-dose JWWJD reduced tumor volume by 27.76% compared to control (P < 0.001). Transcriptomic analysis revealed that JWWJD treatment led to significant downregulation of SPP1 (Fold Change = 0.687, FDR < 0.05), a gene highly associated with poor prognosis in NSCLC patients. Using LC-MS/MS, curcumol was identified as the key active component in JWWJD. Molecular studies demonstrated that curcumol directly binds to SPP1 with strong affinity (KD = 4.55× 10− 6 M), downregulates its expression, and inhibits NSCLC cell migration and invasion. In vivo experiments showed that curcumol reduced tumor volume by 24.88% (P < 0.001). Conclusion: Our study, integrating transcriptomics, bioinformatics, LC-MS/MS, and experimental validation, revealed that JWWJD alleviates NSCLC metastasis by directly targeting SPP1. JWWJD and its active compound curcumol show promise as alternative therapies for NSCLC patients.

8 November 2024 in Medicine
Verified
Journal Article
Open access
JZJinzhi Zhang
Jinzhi Zhang
ZYZi Yang
Zi Yang
SYShasha Yuan
Shasha Yuan
YDYuanyuan Duan
Yuanyuan Duan
QMQing Miao
Qing Miao
Background: Bronchiectasis clinically manifests airway mucus hypersecretion as mucopurulent sputum production and chronic cough. In the past decade, Tanreqing injection (TRQ) has been often used in clinical practice as an add-on treatment for bronchiectasis in China. Several in vivo studies have indicated that TRQ is effective in improving sputum expectoration and cough in acute exacerbation of bronchiectasis but results of individual studies are inconsistent. Therefore, systematically and critically evaluating the effectiveness and safety of TRQ on mucus hypersecretion and cough in bronchiectasis is necessary. Methods: Randomized controlled trials examining the treatment of bronchiectasis with TRQ were systematically searched from databases including PubMed, Cochrane Library, Embase, Web of Science, Chinese National Knowledge Infrastructure, Vip Information Database, Wanfang data, and Chinese Biomedical Literature Database, based on a preregistered protocol and adhering to Cochrane methods. Pertinent data were taken out from the included studies and a methodological quality assessment was done. R language (version 4.4.1) was used to perform the meta-analysis. Results: Twenty randomized controlled trials involving 1544 patients were analyzed. The results demonstrated that TRQ significantly improved mucus hypersecretion, shortened the duration of cough and phlegm, reduced symptom scores, and enhanced both forced expiratory volume in 1 second and forced vital capacity. Additionally, TRQ effectively lowered inflammatory markers, including C-reactive protein, procalcitonin, white blood cell count, neutrophil count, interleukin-6, and tumor necrosis factor-alpha. Moreover, TRQ increased the partial pressure of oxygen and decreased carbon dioxide pressure. Conclusion: The findings suggest that TRQ positively impacts mucus hypersecretion and mucociliary clearance, leading to improvements in sputum production and cough during bronchiectasis exacerbations, without increasing the risk of adverse effects. TRQ may be considered a viable option for managing bronchiectasis and could serve as a novel mucus-modifying agent.